Article Text

Download PDFPDF
A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib
  1. Pilar Taberner Bonastre1,
  2. Gisela Torres Vicente2,
  3. Manuel Cano-Marron1,
  4. Eva Sese Abizanda2,
  5. Tania Dalila Volta Pardo2,
  6. Joan Antoni Schoenenberger-Arnaiz1
  1. 1Pharmacy, Hospital Universitari Arnau de Vilanova, Lleida, Spain
  2. 2Gastroenterology, Hospital Universitari Arnau de Vilanova, Lleida, Catalunya, Spain
  1. Correspondence to Dr Pilar Taberner Bonastre, Pharmacy, Hospital Universitari Arnau de Vilanova, Lleida, Spain; ptaberner.lleida.ics{at}gencat.cat

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease of autoimmune origin with an estimated prevalence in Spain of 0.39%. Current treatments for UC do not achieve high long-term efficacy. Treatment recommendations in moderate and severe disease involve drugs, but when these options fail, the alternatives are scarce, and surgery is intended to be reserved for the last option. We present the case of a 48-year-old male patient with UC for 23 years, who had failed several lines of treatment. The patient started combined therapy with tofacitinib and vedolizumab. These drugs have different mechanisms of action, achieving an immune response and reducing gastrointestinal inflammation. The patient’s disease symptoms improved 11 months after starting this treatment, and he is now entirely asymptomatic. Analytical parameters related to the disease have also shown improvement, and the patient has so far avoided the need for surgical intervention.

  • case reports
  • digestive system diseases
  • inflammatory bowel diseases
  • safety
  • pharmacy service
  • hospital

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.